Evidence map›Paper›PMID 42181273›Full record

ArticleiScience2026

Ceritinib induces ferroptosis via TRIM21-mediated GLUT1 ubiquitination and AMPK-driven metabolic reprogramming in breast cancer.

Yao Chen, Changchang Liu, Ruonan Zhen, Jiarui Li, Yanran Li, Ziying Zhang, Jingying Zhang, Feng Gao, Yongli Bao, Luguo Sun and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yao ChenNMPA Key Laboratory for Quality Control of Cell and Gene Therapy Medicine Products, Northeast Normal University, Changchun 130024, China.
Changchang LiuDepartment of Railway Power Supply, Heilongjiang Communications Polytechnic, Harbin 150025, China.
Ruonan ZhenHebei International Travel Healthcare Center (Shijiazhuang Customs Port Clinic), No. 35, Yangguang Road, Zhengding New District, Shijiazhuang, Hebei Province 050000, China.
Jiarui LiNational Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130117, China.
Yanran LiNational Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130117, China.
Ziying ZhangNational Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130117, China.
Jingying ZhangNational Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130117, China.
Feng GaoNational Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130117, China.
Yongli BaoNMPA Key Laboratory for Quality Control of Cell and Gene Therapy Medicine Products, Northeast Normal University, Changchun 130024, China.
Luguo SunNMPA Key Laboratory for Quality Control of Cell and Gene Therapy Medicine Products, Northeast Normal University, Changchun 130024, China.
Shuyue WangNational Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130117, China.
Lihua ZhengNMPA Key Laboratory for Quality Control of Cell and Gene Therapy Medicine Products, Northeast Normal University, Changchun 130024, China.
Ying SunNMPA Key Laboratory for Quality Control of Cell and Gene Therapy Medicine Products, Northeast Normal University, Changchun 130024, China.
Guannan WangNMPA Key Laboratory for Quality Control of Cell and Gene Therapy Medicine Products, Northeast Normal University, Changchun 130024, China.
Jiawei LiNMPA Key Laboratory for Quality Control of Cell and Gene Therapy Medicine Products, Northeast Normal University, Changchun 130024, China.
Xiaoguang YangNMPA Key Laboratory for Quality Control of Cell and Gene Therapy Medicine Products, Northeast Normal University, Changchun 130024, China.
Zhenbo SongNMPA Key Laboratory for Quality Control of Cell and Gene Therapy Medicine Products, Northeast Normal University, Changchun 130024, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although ceritinib, a potent ALK inhibitor, has been clinically approved for the treatment of non-small cell lung cancer, its potent cytotoxic activity against breast cancer cells and the underlying mechanisms remain largely unknown. We show that ceritinib inhibits proliferation and induces ferroptosis in breast cells. Mechanistically, ceritinib downregulates GLUT1, impairing glycolysis, inducing energy stress, and activating AMPK signaling. Activated AMPK promotes ferritinophagy, leading to iron accumulation, lipid peroxidation, and redox imbalance, ultimately triggering ferroptosis. Rescue experiments demonstrate that GLUT1 overexpression or AMPK inhibition attenuates these effects, confirming the role of the GLUT1-AMPK axis. At the molecular level, ceritinib promotes TRIM21-mediated ubiquitination and proteasomal degradation of GLUT1 through direct binding.

Indexed as

CancerMolecular biologyPharmacology

Identifiers

PMID42181273
PMCPMC13195780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.